Variantyx Inc.

Be sure to attend Alina Sitaula's talk at #CGCAnnual2023 on OncoAlly hereditary cancer and solid tumor testing, happening today at 4:30pm. When cancer's in your sights, #WeSeeMore. Learn more 👉 ow.ly/Kont50PyNBP #hereditarycancer #cancertesting

Just 13 days following ACMG's published update, at Variantyx we've updated our ACMG secondary findings to version 3.2. Find out how by reading our news story: ow.ly/5HN650P3Zhf #genechat #WeSeeMore

The list goes on ... All in a single #wholegenome test.

Variantyx #wholegenome testing identifies DMD variants missed by other technologies, providing a definitive genetic diagnosis. Download our latest case study to see why Seeing More with Variantyx testing makes a difference 👉 ow.ly/su2y50OZlKz #WeSeeMore #10000andCounting

Researchers, clinicians and advocates working towards a cure for #Duchenne muscular dystrophy (#DMD) are able to celebrate a significant milestone with the FDA's recent approval of #Elevidys - the first #genetherapy for Duchenne patients.

The #ASCO2023 exhibit floor is open and it's impressive! Stop by and see us at booth # 13039 to learn why, with OncoAlly, "When cancer is in your sights, we see more".

We're all packed and excited to head to Chicago for #ASCO2023. Will we see you there? If so, be sure to stop by booth # 13039 June 3-5 to learn about our OncoAlly testing.

We're onsite today at the #FLAGC annual meeting - stop by to learn why Seeing More with Variantyx testing makes a difference

The exhibit floor is open in Baltimore! Stop by booth # 2126 to learn about #wholegenome testing for sensitive cases and high-risk pregnancies. At Variantyx, we see more so you know more. #ACOG2023 #WeSeeMore

The results are in! We're honored by our 9th place finish in Boston Business Journal's Fast 50 selection of Massachusetts' fastest growing private companies. Thanks #BBJFAST50 for a fun awards night!

With a TAT of just 7 days, Lightning is the fastest way to reach a clear diagnostic outcome in acutely ill neonatal or pediatric patients. See the difference Lightning makes: variantyx.com/lightning #WPAW2023

When there's a sick child in the NICU or PICU, time is of the essence. This is why we're so excited to wrap up #WorldPICU2023 Awareness Week by announcing the launch of Genomic Unity® Lightning Genome Analysis - our ultra rapid #wholegenome test.

It's not too late to sign up for tomorrow's webinar! Earn NSGC-recognized CEU credit while learning about what truly separates WGS from other NGS technologies. Register at ow.ly/uM5V50OeY02

We're excited to share the recent publication of our study validating Oxford Nanopore Technologies long read sequencing for orthogonal confirmation of variants detected by short read-based clinical #wholegenome sequencing. @nanopore Read the article at ow.ly/LZXr50OkFxN

It's another busy month for regional genetic counselor meetings. We're looking forward to being onsite in Illinois, Florida and southern California and hope to see you there!

Join us for a deep dive into what makes WGS different from other NGS technologies. In 30 minutes, you'll learn about the benefits & limitations of individual tests. Attendees will have the option to sign up for CEU credit recognized by NSGC. Register at ow.ly/n8AB50O9Z6E

Happy DNA day! It's a particularly notable one as this year marks the 20th anniversary of the completion of the human genome project and the 75th anniversary of the discovery of DNA's double helix. #DNADay

Our team is onsite at #AANAM, sharing how Variantyx #wholegenome testing is making a difference for pediatric and adult neurology patients.

We're delighted to be part of Boston Business Journal's Fast 50, recognized as one of Massachusetts' fastest-growing private companies. We look forward to joining other honorees at the Fast 50 Awards May 17th.

The WHO turns 75 today! Join us in raising awareness about the importance of #HealthForAll, including those affected by #RareDisease. #WHO75